Dietary monoterpenes derived from plant essential oils have been shown to prevent DMBA-, NMU- and retroviral-ras-initiated rat mammary cancer at various stages of carcinogenesis. Dietary terpenes also induce the complete regression of the majority of large, established mammary carcinomas with an excellent therapeutic ratio. Several important cellular, metabolic and molecular effects have been shown to be associated with prevention and therapy of mammary cancer by terpenes. These findings have led directly to on-going and planned cancer clinical trials.
Aim 1 further characterizes and evaluates the importance of several potential mechanisms underlying cancer prevention at the promotion/progression stage as well as cancer treatment by terpenes. The occurrence and relevance of terpene inhibition of protein isoprenylation and ubiquinone synthesis in vivo will be studied. The ability of terpenes to induce differentiation will be mechanistically addressed in a neuroblastoma cell culture model by exploring the cAMP signaling pathway. Positive findings will be evaluated in terpene-treated mammary carcinomas. The role of recently identified overexpressed proteins, including the mannose-6-phosphate/IGFII receptor and TGFbeta, in carcinomas induced to regress by terpenes will be evaluated for their role in the regression process. In addition, genes differentially expressed in terpene-induced carcinoma regressions will be isolated by a recently developed, integrated and improved subtractive hybridization/differential display method and then characterized.
Aim 2 focuses on providing guidance for future clinical trial designs by evaluating the ability of terpenes to prevent and treat neu-associated DCIS and mammary carcinomas. The therapeutic effects of combining terpenes and HMG-CoA reductase inhibitors will also be evaluated. Accomplishment of these aims will both contribute to our understanding of the etiology and biology of breast cancer and facilitate on-going and future clinical trials of monoterpenes for their prevention and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA038128-13
Application #
2667872
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1984-07-01
Project End
2000-02-29
Budget Start
1998-03-17
Budget End
1999-02-28
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Berchtold, Craig M; Chen, Kai-Shun; Miyamoto, Shigeki et al. (2005) Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res 65:8558-66
Clark, S S; Perman, S M; Sahin, M B et al. (2002) Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16:213-22
Shi, Wenge; Gould, Michael N (2002) Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol. Carcinogenesis 23:131-42
Ripple, G H; Gould, M N; Arzoomanian, R Z et al. (2000) Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6:390-6
Ariazi, E A; Satomi, Y; Ellis, M J et al. (1999) Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59:1917-28
Satomi, Y; Miyamoto, S; Gould, M N (1999) Induction of AP-1 activity by perillyl alcohol in breast cancer cells. Carcinogenesis 20:1957-61
Ren, Z; Gould, M N (1998) Modulation of small G protein isoprenylation by anticancer monoterpenes in in situ mammary gland epithelial cells. Carcinogenesis 19:827-32
Ripple, G H; Gould, M N; Stewart, J A et al. (1998) Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4:1159-64
Ren, Z; Elson, C E; Gould, M N (1997) Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54:113-20
Ariazi, E A; Gould, M N (1996) Consecutive cycles of precise, unidirectional 14-bp deletions using a BseRI/BsgI trimming plasmid. Biotechniques 20:446-8, 450-1

Showing the most recent 10 out of 34 publications